An estimated 13% of women suffer from depression during or after pregnancy, and treating the condition can be a challenge. Treatment decisions are getting even more complex since recent studies raised issues with the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Sheila M. Marcus, MD, the co-director of the Women Mental Health and Infants Program at the University of Michigan in Ann Arbor, discusses how to evaluate risk and make prescribing decisions for expectant mothers.
All articles by Sheila M. Marcus, MD and Kelly Bilodeau
Latest News Your top articles for ThursdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses